BR112016007348A2 - membro de ligação específica que se liga ao receptor do fator de crescimento epidérmico humano 2 (her2) para uso em um método de tratamento do câncer em um paciente, método de tratamento de câncer em um paciente, método de identificação de um câncer em um paciente, método para prognosticar a resposta de um câncer - Google Patents
membro de ligação específica que se liga ao receptor do fator de crescimento epidérmico humano 2 (her2) para uso em um método de tratamento do câncer em um paciente, método de tratamento de câncer em um paciente, método de identificação de um câncer em um paciente, método para prognosticar a resposta de um câncerInfo
- Publication number
- BR112016007348A2 BR112016007348A2 BR112016007348A BR112016007348A BR112016007348A2 BR 112016007348 A2 BR112016007348 A2 BR 112016007348A2 BR 112016007348 A BR112016007348 A BR 112016007348A BR 112016007348 A BR112016007348 A BR 112016007348A BR 112016007348 A2 BR112016007348 A2 BR 112016007348A2
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- her2
- specific binding
- patient cancer
- binding member
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
resumo membro de ligação específica que se liga ao receptor do fator de crescimento epidérmico humano 2 (her2) para uso em um método de tratamento do câncer em um paciente, método de tratamento de câncer em um paciente, método de identificação de um câncer em um paciente, método para prognosticar a resposta de um câncer a invenção se refere ao uso do número de cópias do gene do receptor do fator de crescimento humano epidérmico 2 (her2) e níveis de rnam como biomarcadores para identificar cânceres que irão responder ao tratamento com um membro de ligação específica compreendendo um sítio de ligação ao antígeno her2 engenheirado em uma região de alça estrutural de um domínio constante, por exemplo, domínio ch3, do membro de ligação específica, e membros de ligação específica que competem com tal membro de ligação para a ligação a her2. 1/1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1317622.7A GB201317622D0 (en) | 2013-10-04 | 2013-10-04 | Cancer biomarkers and uses thereof |
| PCT/GB2014/052994 WO2015049537A1 (en) | 2013-10-04 | 2014-10-03 | Cancer biomarkers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016007348A2 true BR112016007348A2 (pt) | 2018-01-23 |
Family
ID=49630223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016007348A BR112016007348A2 (pt) | 2013-10-04 | 2014-10-03 | membro de ligação específica que se liga ao receptor do fator de crescimento epidérmico humano 2 (her2) para uso em um método de tratamento do câncer em um paciente, método de tratamento de câncer em um paciente, método de identificação de um câncer em um paciente, método para prognosticar a resposta de um câncer |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20160289336A1 (pt) |
| EP (1) | EP3052647B1 (pt) |
| JP (1) | JP6449308B2 (pt) |
| KR (1) | KR20160092992A (pt) |
| CN (1) | CN105722997A (pt) |
| AU (1) | AU2014330942A1 (pt) |
| BR (1) | BR112016007348A2 (pt) |
| CA (1) | CA2925186A1 (pt) |
| CL (1) | CL2016000777A1 (pt) |
| DK (1) | DK3052647T3 (pt) |
| EA (1) | EA201690450A1 (pt) |
| ES (1) | ES2687783T3 (pt) |
| GB (1) | GB201317622D0 (pt) |
| HK (1) | HK1221746A1 (pt) |
| HR (1) | HRP20181566T1 (pt) |
| IL (1) | IL244510A0 (pt) |
| LT (1) | LT3052647T (pt) |
| MX (1) | MX2016004286A (pt) |
| PE (1) | PE20160950A1 (pt) |
| SG (1) | SG11201602605TA (pt) |
| WO (1) | WO2015049537A1 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2594356C (en) | 2005-01-05 | 2018-07-17 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| WO2009000006A1 (en) | 2007-06-26 | 2008-12-31 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Display of binding agents |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| TW201642897A (zh) * | 2015-04-08 | 2016-12-16 | Ｆ 星生物科技有限公司 | Ｈｅｒ２結合劑治療 |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| JP7198752B2 (ja) | 2016-08-09 | 2023-01-04 | カイマブ・リミテッド | 抗ｉｃｏｓ抗体 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
| CN107868814A (zh) * | 2017-12-19 | 2018-04-03 | 威海威仕泰医疗科技有限公司 | 一种用于检测HER2基因的Dig标记探针的制备方法 |
| TWI790370B (zh) | 2018-04-02 | 2023-01-21 | 美商必治妥美雅史谷比公司 | 抗trem-1抗體及其用途 |
| CN108875302B (zh) * | 2018-06-22 | 2022-02-22 | 广州漫瑞生物信息技术有限公司 | 一种检测细胞游离肿瘤基因拷贝数变异的系统和方法 |
| GB201811408D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| KR102325731B1 (ko) * | 2020-01-15 | 2021-11-15 | 주식회사 베르티스 | 암의 진단용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2594356C (en) * | 2005-01-05 | 2018-07-17 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| WO2009000006A1 (en) * | 2007-06-26 | 2008-12-31 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Display of binding agents |
| EP2113255A1 (en) * | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| SG10201507044PA (en) * | 2009-05-29 | 2015-10-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| EP2407487A1 (en) * | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
-
2013
- 2013-10-04 GB GBGB1317622.7A patent/GB201317622D0/en not_active Ceased
-
2014
- 2014-10-03 WO PCT/GB2014/052994 patent/WO2015049537A1/en active Application Filing
- 2014-10-03 CN CN201480055024.5A patent/CN105722997A/zh active Pending
- 2014-10-03 JP JP2016546183A patent/JP6449308B2/ja not_active Expired - Fee Related
- 2014-10-03 BR BR112016007348A patent/BR112016007348A2/pt not_active Application Discontinuation
- 2014-10-03 KR KR1020167011055A patent/KR20160092992A/ko not_active Application Discontinuation
- 2014-10-03 DK DK14781645.8T patent/DK3052647T3/en active
- 2014-10-03 ES ES14781645.8T patent/ES2687783T3/es active Active
- 2014-10-03 PE PE2016000450A patent/PE20160950A1/es not_active Application Discontinuation
- 2014-10-03 SG SG11201602605TA patent/SG11201602605TA/en unknown
- 2014-10-03 MX MX2016004286A patent/MX2016004286A/es unknown
- 2014-10-03 AU AU2014330942A patent/AU2014330942A1/en not_active Abandoned
- 2014-10-03 EP EP14781645.8A patent/EP3052647B1/en active Active
- 2014-10-03 CA CA2925186A patent/CA2925186A1/en not_active Abandoned
- 2014-10-03 LT LTEP14781645.8T patent/LT3052647T/lt unknown
- 2014-10-03 EA EA201690450A patent/EA201690450A1/ru unknown
-
2016
- 2016-03-08 IL IL244510A patent/IL244510A0/en unknown
- 2016-03-31 US US15/087,272 patent/US20160289336A1/en not_active Abandoned
- 2016-04-04 CL CL2016000777A patent/CL2016000777A1/es unknown
- 2016-08-17 HK HK16109856.6A patent/HK1221746A1/zh not_active IP Right Cessation
-
2018
- 2018-10-02 HR HRP20181566TT patent/HRP20181566T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3052647T (lt) | 2018-10-25 |
| JP6449308B2 (ja) | 2019-01-09 |
| CN105722997A (zh) | 2016-06-29 |
| GB201317622D0 (en) | 2013-11-20 |
| CL2016000777A1 (es) | 2017-02-17 |
| WO2015049537A1 (en) | 2015-04-09 |
| CA2925186A1 (en) | 2015-04-09 |
| JP2016533395A (ja) | 2016-10-27 |
| EA201690450A1 (ru) | 2016-10-31 |
| KR20160092992A (ko) | 2016-08-05 |
| DK3052647T3 (en) | 2018-10-22 |
| EP3052647B1 (en) | 2018-07-11 |
| PE20160950A1 (es) | 2016-10-02 |
| ES2687783T3 (es) | 2018-10-29 |
| US20160289336A1 (en) | 2016-10-06 |
| SG11201602605TA (en) | 2016-04-28 |
| AU2014330942A1 (en) | 2016-05-19 |
| HK1221746A1 (zh) | 2017-06-09 |
| MX2016004286A (es) | 2017-01-18 |
| EP3052647A1 (en) | 2016-08-10 |
| HRP20181566T1 (hr) | 2018-11-30 |
| IL244510A0 (en) | 2016-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016007348A2 (pt) | membro de ligação específica que se liga ao receptor do fator de crescimento epidérmico humano 2 (her2) para uso em um método de tratamento do câncer em um paciente, método de tratamento de câncer em um paciente, método de identificação de um câncer em um paciente, método para prognosticar a resposta de um câncer | |
| BR112019008494A2 (pt) | anticorpos para pd-1 e usos dos mesmos | |
| CY1121723T1 (el) | Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων | |
| BR112018005164A2 (pt) | anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de um indivíduo que tem câncer | |
| CY1119799T1 (el) | Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου | |
| MX2017015260A (es) | Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer. | |
| CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
| BR112015022934A2 (pt) | esteroides neuroativos, composições, e uso do mesmo | |
| BR112018000696A2 (pt) | ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit? | |
| BR112017020893A2 (pt) | método para o tratamento de câncer | |
| BR112016014284A2 (pt) | anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo | |
| BR112014023005A2 (pt) | diagnóstico rápido e tratamentos personalizados para acne | |
| BR112014018331A8 (pt) | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação | |
| BR112016016699A2 (pt) | Anticorpos humanos para pd-1 | |
| BR112017012954A2 (pt) | composições e métodos para anticorpos que têm como alvo a bmp6 | |
| UY34815A (es) | Anticuerpos biespecíficos y sus métodos de uso | |
| CR20150247A (es) | Anticuerpos de antihemaglutinina y métodos de uso | |
| BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
| BR112014012590A8 (pt) | Anticorpos anti-cd98 e métodos de uso dos mesmos | |
| BR112018008799A2 (pt) | método de prognóstico | |
| BR112017013111A2 (pt) | métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo | |
| BR112014032728A2 (pt) | uso de marcadores no diagnóstico e tratamento de câncer de próstata | |
| BR112015031710A2 (pt) | anticorpos para o receptor de ldl oxidada similar à lectina 1 e métodos de uso | |
| BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário | |
| CY1121749T1 (el) | Προφαρμακα ανταγωνιστων nmda |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |